氨甲环酸对成人脊柱畸形手术中失血、D-二聚体和纤维蛋白原动力学的影响
该回顾性队列研究纳入2010年1月至2016年7月在本机构接受成人脊柱畸形手术矫正的连续患者,按是否在方案中加入氨甲环酸进行配对,各17例。结果显示氨甲环酸组估计失血量、浓缩红细胞输注量、D-二聚体升高幅度及纤维蛋白原消耗均显著低于对照组。作者结论认为静脉给予氨甲环酸可有效减少术中失血,并通过减少纤维蛋白原消耗和血块溶解阻碍纤溶途径。证据等级为治疗性III级。
要点
- 氨甲环酸组估计失血量为932±539 mL,显著低于对照组的1,800±1,029 mL(p=0.005)。
- 氨甲环酸组浓缩红细胞输注量为1.5±1.6单位,显著低于对照组的4.0±2.1单位(p=0.001)。
- 氨甲环酸组D-二聚体升高幅度由对照组的8.3±5.0 μg/mL降至3.3±3.2 μg/mL(p<0.001)。
核心结论
- 在成人脊柱畸形手术患者中,静脉给予氨甲环酸可有效减少术中失血。
- 术中监测D-二聚体和纤维蛋白原提示,氨甲环酸通过减少纤维蛋白原消耗和血块溶解(表现为D-二聚体生成减少)阻碍纤溶途径。
研究设计与样本
- 回顾性研究,纳入2010年1月至2016年7月在本机构接受成人脊柱畸形手术矫正的连续患者。
- 对方案中加入氨甲环酸前后患者的术中止血数据、手术时间、估计失血量和输血记录进行分析。
- 每例接受氨甲环酸且符合纳入标准的患者与一例未接受氨甲环酸手术的患者进行队列配对。
- 氨甲环酸队列17例,平均年龄60.7岁;对照队列17例,平均年龄60.9岁。
主要发现
- 氨甲环酸组估计失血量为932±539 mL,对照组为1,800±1,029 mL(p=0.005),氨甲环酸组显著更低。
- 氨甲环酸组浓缩红细胞输注量为1.5±1.6单位,对照组为4.0±2.1单位(p=0.001),氨甲环酸组显著更低。
- 在所有符合纳入标准的单阶段手术中,D-二聚体升高幅度由对照组的8.3±5.0 μg/mL降至氨甲环酸组的3.3±3.2 μg/mL(p<0.001)。
- 纤维蛋白原消耗在对照组为98.4±42.6 mg/dL,在氨甲环酸组降至60.6±35.1 mg/dL(p=0.004)。
关键数值与推荐
- 证据等级:治疗性III级。
临床怎么用
- 作者结论认为,在脊柱手术患者中静脉给予氨甲环酸可有效减少术中失血。
- 作者结论认为,术中监测D-二聚体和纤维蛋白原提示氨甲环酸通过减少纤维蛋白原消耗和D-二聚体生成阻碍纤溶途径。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antifibrinolytics such as tranexamic acid reduce operative blood loss and blood product transfusion requirements in patients undergoing surgical correction of scoliosis. The factors involved in the unrelenting coagulopathy seen in scoliosis surgery are not well understood. One potential contributor is activation of the fibrinolytic system during a surgical procedure, likely related to clot dissolution and consumption of fibrinogen. The addition of tranexamic acid during a surgical procedure may mitigate the coagulopathy by impeding the derangement in D-dimer and fibrinogen kinetics. METHODS: We retrospectively studied consecutive patients who had undergone surgical correction of adult spinal deformity between January 2010 and July 2016 at our institution. Intraoperative hemostatic data, surgical time, estimated blood loss, and transfusion records were analyzed for patients before and after the addition of tranexamic acid to our protocol. Each patient who received tranexamic acid and met inclusion criteria was cohort-matched with a patient who underwent a surgical procedure without tranexamic acid administration. RESULTS: There were 17 patients in the tranexamic acid cohort, with a mean age of 60.7 years, and 17 patients in the control cohort, with a mean age of 60.9 years. Estimated blood loss (932 ± 539 mL compared with 1,800 ± 1,029 mL; p = 0.005) and packed red blood-cell transfusions (1.5 ± 1.6 units compared with 4.0 ± 2.1 units; p = 0.001) were significantly lower in the tranexamic acid cohort. In all single-stage surgical procedures that met inclusion criteria, the rise of D-dimer was attenuated from 8.3 ± 5.0 μg/mL in the control cohort to 3.3 ± 3.2 μg/mL for the tranexamic acid cohort (p < 0.001). The consumption of fibrinogen was 98.4 ± 42.6 mg/dL in the control cohort but was reduced in the tranexamic acid cohort to 60.6 ± 35.1 mg/dL (p = 0.004). CONCLUSIONS: In patients undergoing spinal surgery, intravenous administration of tranexamic acid is effective at reducing intraoperative blood loss. Monitoring of D-dimer and fibrinogen during spinal surgery suggests that tranexamic acid impedes the fibrinolytic pathway by decreasing consumption of fibrinogen and clot dissolution as evidenced by the reduced formation of D-dimer. LEVEL OF EVIDENCE: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
引用
- Pong RP, Leveque JA, Edwards A, et al. Effect of Tranexamic Acid on Blood Loss, D-Dimer, and Fibrinogen Kinetics in Adult Spinal Deformity Surgery. J Bone Joint Surg Am. 2018. PMID: 29715224. doi:10.2106/JBJS.17.00860
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。